rolipram has been researched along with Endotoxin Shock in 5 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " As a selective phosphodiesterase-4 inhibitor, rolipram also exhibits the abilities of inhibiting multiple pro-inflammatory cytokines production in macrophages and toxin-induced inflammation in mice." | 7.96 | Rolipram Protects Mice from Gram-negative Bacterium Escherichia coli-induced Inflammation and Septic Shock. ( Chen, X; Jiang, Y; Lu, X; Pan, ZK; Wang, J, 2020) |
| " As a selective phosphodiesterase-4 inhibitor, rolipram also exhibits the abilities of inhibiting multiple pro-inflammatory cytokines production in macrophages and toxin-induced inflammation in mice." | 3.96 | Rolipram Protects Mice from Gram-negative Bacterium Escherichia coli-induced Inflammation and Septic Shock. ( Chen, X; Jiang, Y; Lu, X; Pan, ZK; Wang, J, 2020) |
| " We then report the in vivo anti-inflammatory effect of PDE-IV inhibition in five murine models of inflammation: (i) elevation of serum TNF-alpha induced by a sublethal LPS injection; (ii) LPS-induced endotoxic shock; (iii) LPS/galactosamine-induced endotoxic shock; (iv) carrageenan-induced paw oedema; and (v) adjuvant arthritis." | 3.69 | Anti-inflammatory activity of phosphodiesterase (PDE)-IV inhibitors in acute and chronic models of inflammation. ( Bateman-Fite, R; Brackeen, MF; Clark, RL; Connolly, KM; Menius, JA; Noel, LS; Sekut, L; Stimpson, SA; Yarnall, D, 1995) |
| "In CD14+ monocytes of patients with septic shock, the anti-inflammatory effect of isoprenaline was completely blunted whereas efficacy of forskolin and rolipram was maintained." | 1.35 | Phosphodiesterase 4 inhibition but not beta-adrenergic stimulation suppresses tumor necrosis factor-alpha release in peripheral blood mononuclear cells in septic shock. ( Böhm, M; Lenz, M; Link, A; Maack, C; Selejan, S, 2008) |
| "In a model of septic shock, i." | 1.29 | Protection by phosphodiesterase inhibitors against endotoxin-induced liver injury in galactosamine-sensitized mice. ( Fischer, W; Schudt, C; Wendel, A, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (60.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lu, X | 1 |
| Wang, J | 1 |
| Chen, X | 1 |
| Jiang, Y | 1 |
| Pan, ZK | 1 |
| Link, A | 1 |
| Selejan, S | 1 |
| Maack, C | 1 |
| Lenz, M | 1 |
| Böhm, M | 1 |
| Badger, AM | 1 |
| Olivera, DL | 1 |
| Esser, KM | 1 |
| Sekut, L | 1 |
| Yarnall, D | 1 |
| Stimpson, SA | 1 |
| Noel, LS | 1 |
| Bateman-Fite, R | 1 |
| Clark, RL | 1 |
| Brackeen, MF | 1 |
| Menius, JA | 1 |
| Connolly, KM | 1 |
| Fischer, W | 1 |
| Schudt, C | 1 |
| Wendel, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Fluoxetine to Reduce Hospitalization From COVID-19 Infection (FloR COVID-19)[NCT04570449] | Early Phase 1 | 0 participants (Actual) | Interventional | 2020-11-30 | Withdrawn (stopped due to Study timeline is not feasible) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 other studies available for rolipram and Endotoxin Shock
| Article | Year |
|---|---|
Rolipram Protects Mice from Gram-negative Bacterium Escherichia coli-induced Inflammation and Septic Shock.
Topics: Animals; Anti-Inflammatory Agents; Cytokines; Escherichia coli; Escherichia coli Infections; Inflamm | 2020 |
Phosphodiesterase 4 inhibition but not beta-adrenergic stimulation suppresses tumor necrosis factor-alpha release in peripheral blood mononuclear cells in septic shock.
Topics: Adrenergic beta-2 Receptor Agonists; Case-Control Studies; Colforsin; Flow Cytometry; GTP-Binding Pr | 2008 |
Beneficial effects of the phosphodiesterase inhibitors BRL 61063, pentoxifylline, and rolipram in a murine model of endotoxin shock.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Cells, Cultured; Cyclic Nucleotide Phosphodiesterases, | 1994 |
Anti-inflammatory activity of phosphodiesterase (PDE)-IV inhibitors in acute and chronic models of inflammation.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Carrageenan; Female; Gala | 1995 |
Protection by phosphodiesterase inhibitors against endotoxin-induced liver injury in galactosamine-sensitized mice.
Topics: Animals; Cells, Cultured; Colforsin; Cyclic AMP; Dinoprostone; Galactosamine; Hepatitis; Lipopolysac | 1993 |